Ercc1 Remains A Predictive Marker of the Benefit of Adjuvant Chemotherapy (Ct) in the Updated International Lung Cancer Trial (Ialt)

Ercc1 Remains A Predictive Marker of the Benefit of Adjuvant Chemotherapy (Ct) in the Updated International Lung Cancer Trial (Ialt)

2008 Annals of Oncology

Soria, J.C. | Olaussen, K.A. | Vataire, A.L. | Dunant, A. | Pirker, R. | Besse, B. | Andre, F. | Brambilla, E. | Le Chevalier, T. | Fouret, P. | Volume: 19 [suppl.8], Issue: 92, Pages: ,